Deborah A Griffin Net Worth

The estimated Net Worth of Deborah A Griffin is at least $17 Tisíc dollars as of 17 March 2020. Deborah Griffin owns over 944 units of Teva- Pharmaceutical Industries stock worth over $16,954 and over the last 7 years Deborah sold TEVA stock worth over $0.

Deborah Griffin TEVA stock SEC Form 4 insiders trading

Deborah has made over 4 trades of the Teva- Pharmaceutical Industries stock since 2019, according to the Form 4 filled with the SEC. Most recently Deborah exercised 944 units of TEVA stock worth $16,954 on 17 March 2020.

The largest trade Deborah's ever made was exercising 4,807 units of Teva- Pharmaceutical Industries stock on 4 March 2020 worth over $86,334. On average, Deborah trades about 874 units every 13 days since 2018. As of 17 March 2020 Deborah still owns at least 944 units of Teva- Pharmaceutical Industries stock.

You can see the complete history of Deborah Griffin stock trades at the bottom of the page.

What's Deborah Griffin's mailing address?

Deborah's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL STREET, PETACH TIKVA, L3, 4951033.

Insiders trading at Teva- Pharmaceutical Industries

Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks a Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.

What does Teva- Pharmaceutical Industries do?

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Complete history of Deborah Griffin stock trades at Teva- Pharmaceutical Industries

Teva- Pharmaceutical Industries executives and stock owners

Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include:

• Kaare Schultz,
  President, Chief Executive Officer, Director
• Kare Schultz,
  Pres, CEO & Director
• Mark Sabag,
  Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
• Hafrun Fridriksdottir,
  Executive Vice President - Global R&D
• Brendan O'Grady,
  Executive Vice President - North America Commercial
• Gianfranco Nazzi,
  Executive Vice President - International Markets Commercial
• Dr. Hafrun Fridriksdottir,
  Exec. VP of Global R&D
• Gianfranco Nazzi,
  Exec. VP of International Markets Commercial
• Eric Drape,
  Exec. VP of Global Operations
• Eliyahu Sharon Kalif,
  Exec. VP & CFO
• Sol Barer,
  Independent Chairman of the Board
• Nechemia Peres,
  Independent Director
• Gerald Lieberman,
  Independent Director
• Amir Elstein,
  Independent Director
• Roberto Mignone,
  Independent Director
• Rosemary Crane,
  Independent Director
• Jean-Michel Halfon,
  Independent Director
• Perry Nisen,
  Independent Director
• Ronit Satchi-Fainaro,
  Independent Director
• Eliyahu Kalif,
  Chief Financial Officer, Executive Vice President
• Kevin Mannix,
  Senior Vice President, Investor Relations
• Janet Vergis,
  Independent Director
• Abbas Hussain,
  Independent Director
• David Stark,
  Executive Vice President, Chief Legal Officer
• Eric Drape,
  Executive Vice President - Global Operations
• Sven Dethlefs,
  Executive Vice President - Global Marketing & Portfolio
• Richard Daniell,
  Executive Vice President - European Commercial
• Eli Shani,
  Exec. VP of Global Marketing & Portfolio
• Galia Inbar,
  Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG
• David M. Stark,
  Exec. VP & Chief Legal Officer
• Amir Weiss,
  Sr. VP & Chief Accounting Officer
• Lori Queisser,
  Sr. VP & Global Compliance Officer
• Andrew J. Weil CPA,
  Chief Accounting Officer
• Eric Drapé,
  Exec. VP of Global Operations
• Iris Beck Codner,
  EVP Global Brand&Communication
• Kare Schultz,
  President and CEO
• Michael James Mc Clellan,
  EVP, Chief Financial Officer
• Notaristefani Carlo De,
  Executive VP Global Operations
• Placid Jover,
  See "Remarks"
• Deborah A Griffin,
  Chief Accounting Officer
• Varda Shalev,
  
• Dan S Suesskind,
  Director
• Murray A Goldberg,
  Director
• Dov Bergwerk,
  Acting Chief Legal Officer
• David R. Mc Avoy,
  EVP, Chief Legal Officer
• Andrew Weil,
  Chief Accounting Officer
• Galia Inbar,
  See "Remarks"
• Eli Shani,
  EVP,Global Marketing&Portfolio
• Angus Grant,
  EVP, Business Development
• Eric A Hughes,
  See "Remarks"
• Vikki L Conway,
  See "Remarks"
• Christine Fox,
  EVP, Head of U.S. Commercial
• Amir Weiss,
  Chief Accounting Officer
• Richard D Francis,
  President and CEO
• Matthew Shields,
  EVP, Global Operations
• Tal Zvi Zaks,